Spotlight on Clinical Trials
Phase II study of lapatinib and capecitabine in second-line treatment of locally advanced/metastatic pancreatic cancer
This Phase II trial is designed to test vital new treatment options to patients with metastatic pancreatic cancer who have already received and are no longer responding to the standard gemcitabine-based chemotherapy. The trial is specifically designed to evaluate the combination of lapatinib and capecitabine (two chemotherapy agents) in the treatment of gemcitabine-resistant metastatic pancreatic cancer. Patients receive oral lapatinib (once daily) and capecitabine (twice daily) for two consecutive weeks out of every three weeks.
So far, 17 patients have been enrolled on this trial. Each patient’s serum was collected for analysis of biomarkers. Biomarkers are proteins that may change in response to chemotherapy and thus predict clinical outcomes. Further investigation of these markers may help to identify which patient subgroups are more likely to respond to therapy. At Georgetown Lombardi’s Ruesch Center, we strive to win our war against pancreas and other gastrointestinal cancers using innovative trials, molecular medicine and modern technology.
See http://lombardi.georgetown.edu/clinicalprotocols/index.cfm for further trial details.